The insulin-like growth factors (IGFs) are essential for development; bioavailable IGF is tightly regulated by six related IGF-binding proteins (IGFBPs). Igfbp5 is the most conserved and is developmentally up-regulated in key lineages and pathologies; in vitro studies suggest that IGFBP-5 functions independently of IGF interaction. Genetic ablation of individual Igfbps has yielded limited phenotypes because of substantial compensation by remaining family members. Therefore, to reveal Igfbp5 actions in vivo, we generated lines of transgenic mice that ubiquitously overexpressed Igfbp5 from early development. Significantly increased neonatal mortality, reduced female fertility, whole-body growth inhibition, and retarded muscle development were observed in Igfbp5-overexpressing mice. The magnitude of the response in individual transgenic lines was positively correlated with Igfbp5 expression. Circulating IGFBP-5 concentrations increased a maximum of only 4-fold, total and free IGF-I concentrations increased up to 2-fold, and IGFBP-5 was detected in high Mr complexes; however, no detectable decrease in the proportion of free IGF-I was observed. Thus, despite only modest changes in IGF and IGFBP concentrations, the Igfbp5-overexpressing mice displayed a phenotype more extreme than that observed for other Igfbp genetic models. Although growth retardation was obvious prenatally, maximal inhibition occurred postnatally before the onset of growth hormone-dependent growth, regardless of Igfbp5 expression level, revealing a period of sensitivity to IGFBP-5 during this important stage of tissue programming. T he insulin-like growth factors (IGF-I and -II) are essential for growth and development (1). Six high-affinity IGF-binding proteins (IGFBP-1 to IGFBP-6; refs. 2 and 3) strictly orchestrate IGF action. Despite their considerable sequence homology, each exhibits a discrete expression pattern and possesses an individual subset of motifs, signifying that although IGFBPs have common actions, they may also have unique properties.
T he insulin-like growth factors (IGF-I and -II) are essential for growth and development (1) . Six high-affinity IGF-binding proteins (IGFBP-1 to IGFBP-6; refs. 2 and 3) strictly orchestrate IGF action. Despite their considerable sequence homology, each exhibits a discrete expression pattern and possesses an individual subset of motifs, signifying that although IGFBPs have common actions, they may also have unique properties.
IGFBP-5 is the most conserved of the IGFBPs (4) and has been highlighted as a focal regulatory factor during the development of several key cell lineages, e.g., myoblasts (5) and neural cells (6, 7) . In mice, Igfbp5 is expressed in the embryo from early development, principally in the myotomal component of the somites and developing central nervous system (8) . Postnatally, serum IGFBP-5, in common with IGFBP-3, forms a ternary complex with IGF-I or IGF-II and the acid-labile subunit (9) . Igfbp5 is up-regulated in the aggressive pediatric cancer, rhabdomyosarcoma (10) , in the progression of prostate cancers to androgen independence (11) , and in smooth muscle-derived uterine leiomyoma (12) , indicating a function in neoplasia.
IGFBP-5 initially binds IGFs with high affinity, principally by an N-terminal motif (13) , and inhibits IGF activity by preventing IGF interaction with the type 1 receptor. It is further subject to regulated posttranslational modifications (3) to induce conformational changes that decrease its affinity for IGFs and allow their effective delivery to the type 1 receptor. However, IGFBPs are also multifunctional proteins that can regulate cell function independent of IGF signaling (14) (15) (16) ; key motifs that may mediate these functions include a consensus nuclear localization signal (17) and serine͞ threonine phosphorylation sites. These primary motifs are conserved, signifying that putative IGF-dependent and -independent functions have been maintained.
We have therefore pursued the hypothesis that IGFBP-5 has a significant role in growth and development. IGFBP function has been investigated in vivo by using gene ablation by homologous recombination (e.g., ref. 18); however, to date Igfbp-null mice have exhibited a limited phenotype because of compensation and redundancy from remaining IGFBPs. We therefore decided to take an alternative approach and generate transgenic mice overexpressing Igfbp5. These mice are significantly growth-retarded and exhibit the most severe phenotype of any Igfbp genetic manipulation in vivo to date, providing convincing evidence that IGFBP-5, by either IGF-dependent or -independent mechanisms, is important in determining cell fate.
Materials and Methods
Transgene Construction. The murine Igfbp5-coding region [in pEMSVscribe ␣2 (5), P. Rotwein, Oregon Health Sciences University, Portland] was amplified by PCR (primer sequences are given in Supporting Text, which is published as supporting information on the PNAS web site) with use of PfuTurbo (Stratagene) to include the native translation initiation sequence of Igfbp5 and to introduce a C-terminal myc epitope. The EcoRI-restricted, 893-bp Igfbp5-myc amplicon was inserted downstream of the cytomegalovirus enhancer, chicken ␤-actin promoter, and rabbit ␤-globin splice acceptor, and upstream to the simian virus 40 polyadenylation signal of a pCAGGS expression vector (J. Miyazaki, OsakaSouthern and Northern Blot Analyses. Tail genomic DNA was digested with EcoRI for Southern blot analysis. Slot-blot analysis of genomic DNA, in parallel with WT genomic DNA that had been spiked using a serial dilution of transgene, confirmed copy number, and distinguished homo-and hemizygotes. Blots were hybridized with a random-primed, labeled (High Prime protocol, Roche Diagnostics), full-length mouse Igfbp5 cDNA template (S. L. Drop, Erasmus University, Rotterdam, The Netherlands) and H19 probe as a control.
Total RNA was purified from key tissues by using the RNeasy Midi protocol (Qiagen) and analyzed by Northern blotting with random-primed, labeled cDNA probes; Gapdh was used as a loading control. Southern and Northern blot signals were quantified by phosphorimaging.
Circulating IGFBP, Total, and Free IGF-I Concentrations. Serum IGFBP levels were analyzed by ligand blotting (20) with biotinylated human IGF-I (GroPep, Adelaide, Australia). Immunoblotting was performed with anti-human IGFBP-5 polyclonal rabbit Ab (1:250; Upstate Biotechnology, Lake Placid, NY) or anti-myc polyclonal rabbit Ab (1:125; Upstate Biotechnology). Serum total IGF-I concentrations were measured by using a rat IGF-I enzyme immunoassay from Diagnostics Systems Laboratories (DSL; Webster, TX). To measure total serum IGF-I levels, IGF-I was dissociated from IGFBPs before the enzyme immunoassay by using three different methods (21) : (i) acid͞ethanol extraction, according to the DSL protocol, (ii) acidification and ultrafiltration through a Microcon YM-30 device (Millipore), and (iii) acidification and gel filtration by using a Superdex 75 Precision Column (3.2 ϫ 300 mm; Amersham Pharmacia). Free IGF-I levels were measured directly in ultrafiltrates by using the DSL enzyme immunoassay after centrifugation of 50 l of serum with Microcon YM-30 devices.
IGFBP-5-myc in serum binary or ternary complexes was examined by crosslinking proteins in 3 l of serum for 30 min at room temperature with 0.25 mM disuccinimidyl suberate and 10% DMSO, followed by nonreducing 7.5% SDS͞PAGE (22) and immunoblotting with anti-myc Ab.
Real-Time PCR. Total RNA (2 g) was reverse-transcribed with SuperScript II RT (Invitrogen), and resultant cDNA was subjected to real-time PCR (Applied Biosystems). The mRNA levels of Igf1, Igfbp3, Igfbp5, and ␤-actin were assessed (primer sequences given in Supporting Text). The fluorescence of SYBR Green bound to double-stranded DNA was measured after each PCR cycle as the reaction proceeded to completion. A ␤-actin dilution series during the linear phase was used to normalize RNA levels between samples.
Histology. Embryos were embedded in optimum cutting temperature compound and frozen in dry-ice-cooled isopentane. Sagittal sections (10 m) were stained with Gills III hematoxylin͞eosin (BDH). (23), and mouse models overexpressing other Igfbps have invariably displayed multiple copy numbers (e.g., ref.
24).
Ubiquitous Expression of Igfbp5-myc. Northern blot analyses revealed relative transgene expression levels between lines (transcript at 1.0 kb) and demonstrated that line 3 mice exhibited the highest Igfbp5-myc mRNA abundance, with line 1 and 2 mice having intermediate and low expression levels, respectively (Fig. 1B) . These between-line differences were consistently observed for all tissues and ages examined between birth and 8 wk in hemizygous animals and were corroborated by real-time RT-PCR (data not shown). Endogenous Igfbp5 mRNA (5.5 kb) was confirmed in all tissues examined, except liver (Fig. 1C) ; the greatest levels were in kidney, brain, and skeletal muscle. Real-time PCR analysis determined that Igfbp5 mRNA levels were increased by 10-to 20-fold in skeletal muscle of line 3 adults (data not shown). Transgene Igfbp5-myc tended to down-regulate endogenous Igfbp5 expression.
Reduced Litter Size and Increased Morbidity Correlated with High
Igfbp5 Expression. Litter size at birth was decreased in direct correlation with maternal Igfbp5 expression levels when transgenic (Tg) hemizygous females were used for matings with either hemizygous ( Fig. 2) or WT males (although only a few successful matings occurred for line 3 mice because of the size difference in males and females for this cross; data not shown). Reduced litter size was apparent from as early as embryonic day 10.5 (e10.5). Hemizygous males generated WT litter sizes when crossed with WT females.
Litters of Igfbp5-myc-overexpressing mice derived from hemizygous parents also had higher rates of mortality than from WT parents (Fig. 8 , which is published as supporting information on the PNAS web site); line 3 mice exhibited an 8-fold increase in morbidity (P Ͻ 0.01), most occurring by 24 h postnatally. Mendelian inheritance was observed in all lines at birth, but no line 3 homozygotes survived (proportions in 8-wk-old line 3 mice: Ϫ/Ϫ, 10; Ϫ/ϩ, 25; ϩ/ϩ, 0; total ϭ 35; P Ͻ 0.001). Northern blot analysis revealed higher Igfbp5-myc mRNA levels in homozygous than hemizygous mice for all lines (data not shown). We conclude that reduced litter size was due to maternal compromise but that high expression of Igfbp5 was lethal in the early postnatal period.
Growth Retardation in Igfbp5-Overexpressing Mice. Birth weights were reduced for hemizygotes expressing high levels of Igfbp5 (WT, 1.445 Ϯ 0.024 g; line 1, 99.4 Ϯ 2.7%; line 2, 91.7 Ϯ 5.0%, P ϭ 0.18; line 3, 81.9 Ϯ 4.1%, P Ͻ 0.01; % WT weight; generated from WT females ϫ hemizygous males). Birth weight was reduced even further when hemizygous parents were crossed (Fig. 3A) . Line 3 homozygous pups were only 64%, and nontransgenic littermates were 92% WT weight, suggesting that IGFBP-5 influenced prenatal growth by modest indirect effects by way of the mother but by major direct effects on the fetus.
Postnatally, all hemizygous pups were significantly growthretarded by 3 wk to 83.1 Ϯ 5.3% (P ϭ 0.011, line 2), 70.3 Ϯ 4.8% (P Ͻ 0.001, line 1), and 67.0 Ϯ 2.5% (P Ͻ 0.001, line 3) of WT weight (Fig. 3B) ; all WT siblings exhibited control weights. By 8 wk of age, line 1 and 3 females remained growth-retarded (line 1, 77.7 Ϯ 2.2%, P Ͻ 0.001; line 3, 65.1 Ϯ 1.5%, P Ͻ 0.001), whereas line 2 females displayed some catch-up growth (line 2, 97.7 Ϯ 1.8%, NS). For males, growth retardation induced by Igfbp5 overexpression was similar to that of females (8-wk weight as % WT: line 2, 96.3 Ϯ 1.7, NS; line 1, 78.0 Ϯ 1.4, P Ͻ 0.001; line 3, 63.4 Ϯ 1.11, P Ͻ 0.001).
The dependence of growth on Igfbp5 gene dose was further confirmed by crossing hemizygous parents (Fig. 9 , which is published as supporting information on the PNAS web site). At 8 wk this was similar for line 1 homozygous and line 3 hemizygous mice (60-65%), indicating a threshold before Igfbp5 levels become lethal. The mild prenatal growth retardation in WT siblings derived from line 3 hemizygous mothers was overcome by 8 wk, suggesting that any maternal compromise was reversible.
Tissue-Specific Effects of Igfbp5 Overexpression. Absolute tissue weights, except brain tissue, were significantly reduced in transgenic mice that exhibited decreased whole-body weights at 8 wk. Fractional tissue weights (tissue weight͞whole bodyweight) were calculated for mice derived from hemizygote parents (Fig. 4) and from WT mothers crossed with hemizygous fathers (Fig. 10 , which is published as supporting information on the PNAS web site). These weights increased significantly for brain and liver, and decreased for muscle and spleen; these individual tissue responses correlated with transgene expression across lines. Changes in relative tissue weight appeared to be initiated by birth, although these changes did not always reach statistical significance (data not shown). The most significant deviation in relative tissue mass was observed for skeletal muscle, which decreased by 31%. Relative tissue weights for male and female mice responded similarly.
Histological studies corroborated the changes in embryo and tissue weights, with transgenic mice consistently appearing to have a large head relative to the body (Fig. 5A) , an observation supported by the increase in fractional brain weight. Diaphragm muscles of the Igfbp5 animals were thinner (width: WT, 143.6 Ϯ 8.2; line 3 ϩ/ϩ, 101.8 Ϯ 6.4 m; n ϭ 3, P Ͻ 0.05; Fig. 5B ). To assess the mechanism responsible, three adjacent intercostal muscles from each of three WT and line 3 mice were analyzed by two-way ANOVA, because these muscles are discrete bundles. Total bundle area decreased (WT, 0.160; line 3 ϩ/ϩ, 0.099; pooled SEM Ϯ 0.011 mm 2 ; P Ͻ 0.01), whereas the proportion occupied by muscle fibers increased in Igfbp5-overexpressing mice (WT, 67.6; line 3 ϩ/ϩ, 78.0; pooled SEM Ϯ 3.1%; P Ͻ 0.05), and the interfiber tissue area correspondingly decreased. Individual fiber area decreased by Ͼ25%, although only at the 6% significance level (WT, 160; line 3 ϩ/ϩ, 116; pooled SEM Ϯ 15 m 2 ; P ϭ 0.06), whereas total fiber number per bundle remained constant (WT, 697; line 3 ϩ/ϩ, 666; pooled SEM Ϯ 31; NS). Taken together, these data suggest that Igfbp5 overexpression decreased muscle fiber hypertrophy and interfiber tissue formation but did not affect fiber number, and, therefore, each muscle contained a similar number of smaller, more densely packed fibers.
Further, the lungs of homozygotes were more cellular with decreased alveolar separation than in WT animals (Fig. 5C ). In WT animals, IGFBP-3 levels were low at birth and increased gradually up to 8 wk (Fig. 6B) , but the consistent presence of IGFBP-5-myc suppressed this developmental increase.
Total serum IGF-I concentrations were 640 ng͞ml in control mice (Fig. 6C) and paradoxically increased by 33% (P Ͻ 0.05) and 89% (P Ͻ 0.001) in line 1 and line 3 mice, respectively (corroborated by all three methods of IGFBP extraction). Moreover, mRNA levels of Igf1 or Igfbp3 in key tissues were similar in WT and transgenic mice, assessed by real-time RT-PCR (Fig. 11 , which is published as supporting information on the PNAS web site), suggesting that alterations in IGF-I and IGFBP-3 levels observed in Igfbp5 transgenic mice were not due to adaptations in expression.
The ratio of free to total serum IGF-I may represent bioactive IGF (25) . Free to total serum IGF-I levels tended to increase (P ϭ 0.066) in Igfbp5 line 3 hemizygote adults (3.60 Ϯ 0.67%; n ϭ 9) versus WT siblings (1.03 Ϯ 0.94%; n ϭ 5), thus total free IGF-I concentrations increased significantly in the transgenic mice (Tg, 4.79 Ϯ 0.63; WT, 2.05 Ϯ 0.90 ng͞ml; P Ͻ 0.05). IGFBP-5-myc was observed at molecular weights equivalent to those observed for ternary and binary complexes (9) and for free protein, indicating possible interaction with IGFs and acid-labile subunit (Fig. 12 , which is published as supporting information on the PNAS web site).
Discussion
Our findings reveal that IGFBP-5 has an important role in growth and development. Three lines of Igfbp5 transgenic mice were generated that expressed IGFBP-5 at low, intermediate, and high levels; resultant phenotypes spanned a wide physiological range of IGFBP-5 action, from mild growth retardation with catch-up growth, to severe growth retardation and lethality. In contrast to other genetic studies, this report demonstrates a clear effect for an IGFBP in vivo. The significance of these findings is that changes in Igfbp5 expression could modulate developmental progression, in particular, during the critical immediate postnatal period when tissue programming for adaptation to adult metabolism occurs.
The complexity of IGFBP-5 action (3) dictates that its role in development could be due to (i) IGFBP-5 inhibition of IGF-I and͞or IGF-II activity, (ii) IGF-potentiating effects of IGFBP-5, or (iii) IGF-independent actions of IGFBP-5. The first could be considered ''IGFBP-generic'' and, therefore, Igfbp5-overexpressing mice would exhibit characteristics common to other Igfbpoverexpression models, but the latter two options would be IGFBPspecific. At one extreme, IGFBP-5 action would inhibit IGF-I and -II activity, and thus the phenotype of the mice would resemble Igf1 and Igf2 double-null mice. Alternately, IGF-independent actions of IGFBP-5 may be revealed as phenotypic properties divergent from those displayed by Igf1-or Igf2-null mice.
Inhibition of IGF Activity. Overall, the Igfbp5-overexpressing mice demonstrated a consistent and dose-dependent phenotype between lines that, in part, conformed to that for Igf-null animals. The highest expressing Igfbp5 transgenic mice had birth weights that were almost as growth-retarded as either Igf1-or Igf2-null mice (1, 26, 27) and therefore not as extreme as Igf double-null mice (28) , implying that Igfbp5 only partially ablated IGF-I and͞or IGF-II activity. Surprisingly, when growth rate was considered, Igfbp5-overexpressing mice did not conform to the growth pattern of either Igf1-or Igf2-null mice. All surviving Igfbp5 transgenic mice became maximally growth-retarded between birth and 3 wk; the lowest expressing line 2 mice displayed catch-up growth, possibly due to increased postpubertal IGF-I overcoming the modest Igfbp5-myc expression. In contrast, Igf1-null mice become progressively more growth-retarded than WT mice after 3 wk postnatally (29) at the onset of growth hormone-dependent growth (30), whereas Igf2-null mice remain at a constant proportion of WT weight from birth (27) .
Our data therefore reveal a critical period of sensitivity to Igfbp5 expression levels between birth and before the onset of growth hormone-stimulated IGF-I synthesis (2-3 wk). This sensitivity is possibly because Igf2 expression declines during the first 3 wk in mice before increased Igf1 expression. In support of this hypothesis, serum concentrations of the main circulating IGFBP (IGFBP-3) remain suppressed until after 2-3 wk postnatally (Fig. 6 and ref. 3) . In terms of overall growth rate, the phenotype of Igfbp5-overexpressing mice more closely resembled Igf2-than Igf1-null mice, reflecting the higher affinity of IGFBP-5 for IGF-II (13) . Further support for inhibition of IGF-II action is derived from the strongly compromised muscle development observed in the Igfbp5 transgenics; Igf2 and Igfbp5 are highly up-regulated in differentiating myoblasts (4), and, therefore, our observations are consistent with the suggestion that they have critical roles in myogenesis (31) .
Potentiation of IGF Activity. A striking phenotype observed for Igfbp5-overexpressing mice was the increased brain fractional weight. In marked contrast, overexpression of Igfbp1 or Igfbp3 induced decreased fractional brain weight (24, 32) with Igfbp2 overexpression having little effect (33) . IGFBP-5 has been proposed to potentiate IGF-I activity in neural tissue (7), and Igfbp5 and Igf1 are coexpressed in brain (34); thus, it is possible that the relative increase in brain weight was due to the targeting of IGF activity to type 1 receptors by IGFBP-5. Even though hepatic tissue does not express Igfbp5 in WT mice, liver fractional weight was also increased in Igfbp5-overexpressing mice. Because IGF type 1 receptors are only expressed in fetal not adult liver, Igfbp5 ''abnormally'' expressed in the livers of transgenic mice could have performed a similar potentiating function prenatally, with postnatal effects due to IGF-independent actions of IGFBP-5.
IGF-Independent Actions of IGFBP-5.
A proportion of Igf1-null mice die at birth, depending on genetic background (1). Because we have evidence for only partial ablation of IGF-I activity, the absolute morbidity of the highest expressing Igfbp5 homozygous mice was unexpected. ''Midi'' mice have very reduced Igf1 expression levels and are about the same size as the high-expressing hemizygous Igfbp5 transgenic mice, yet they are completely viable (35) . Further, Igf2-null mice are smaller and are viable (27) . Therefore, the lethality observed in Igfbp5 transgenics is unlikely because of their reduced birth weight. However, until the cause of death in Igfbp5 transgenics is determined, it is difficult to conclude whether mainly IGF-dependent or -independent actions of IGFBP-5 were responsible. In addition, a dose-dependent sexually dimorphic decrease in fertility was observed in Igfbp5-overexpressing mice, with female but not male transgenic parents generating litters of reduced size. Igf2 nulls have no defects in fertility, but surviving Igf1 nulls of both genders are infertile (30) . Recently, it has been suggested that IGFBP-5 may inhibit cell growth and be proapoptotic in an IGF-independent manner (36) , which might provide a mechanism for the surprising morbidity and reduced female fertility.
Comparison of the Igfbp5 transgenic mice generated here with other models of constitutive Igfbp overexpression provides further insight into generic versus unique actions of the IGFBP family. Igfbp5-overexpressing mice were much more growth-retarded than other Igfbp transgenics despite expression of equivalent amounts of IGFBP protein. Indeed, the lack of phenotype in other Igfbp overexpression models has always been surprising. For example, the cytomegalovirus and phosphoglycerate kinase promoters used to overexpress Igfbp1 (37), Igfbp2 (33) , and Igfbp3 (24) displayed negligible or only modest changes in growth rate. These phenotypes could often only be observed in homozygous animals despite substantial increases in circulating IGFBP concentrations that exceeded the 4-fold increase we observed in the highest Igfbp5-expressing line. Further, any decreased growth usually occurred by birth or after the onset of growth hormone-dependent growth, consistent with inhibition of IGF-I activity, in contrast to the critical period of growth inhibition observed between birth and 3 wk for the Igfbp5-overexpressing mice. Collectively, these data suggest that IGFBP-5 may have important functions that are not related to modulation of IGF activity and support the increasing number of observations that IGFBP-5 has additional IGF-independent actions (15, 16, 36) .
Clinical Significance of Increased Igfbp5 Expression. The importance of circulating IGF and IGFBP concentrations has been unequivocally demonstrated by using mice doubly null for liver Igf1 and Als (25) . Further, the molecular form of serum IGF is crucial, i.e., whether it is free or bound to individual IGFBPs, each of which may be modified in various ways to modify their interaction with the IGFs. In this study, despite increased total serum IGF-I levels, Igfbp5 transgenics were growth-retarded, consistent with an inhibition of IGF access to tissue receptors. It was surprising, therefore, that the proportion of free IGF-I in serum tended to increase in Igfbp5-overexpressing mice, although this also occurred in the growth-retarded liver Igf1 and Als double-null mice (25) . The proportion of different IGFBPs in serum is also important, and, in this regard, IGFBP-5 can effectively compete with IGFBP-3 for serum ternary complex formation with the acid-labile subunit in vivo (38) . The demonstration of IGFBP-5-myc protein at an appropriate M r for ternary complex formation suggests that IGFBP-5 could have displaced IGFBP-3 from this complex, retaining circulating IGF in a relatively tightly bound ternary complex (39) . Because noncomplexed IGFBP-3 is susceptible to proteolysis (40) , the decrease in circulating IGFBP-3 concentrations was consistent with degradation of displaced IGFBP-3.
Elevations in circulating IGF-I concentrations have been associated with increased risk of colorectal (41) , breast (42) , and prostate (43) cancers, clinically and experimentally (44) . This relationship is strengthened when circulating IGFBP-3 concentrations are also considered (41, 43) , which are negatively correlated with cancer risk and are proposed to inhibit or counteract IGF-I activity. Because the phenotype of the Igfbp5-overexpressing mice in this study displays some properties consistent with inhibition of IGF-I activity, the propensity for neoplasia may be reduced in the Igfbp5-overexpressing mice. Indeed, a recent study suggests that IGFBP-5 inhibits survival of breast cancer cells (36) .
In summary, we demonstrate a significant role for IGFBP-5 in growth and development. Our findings suggest key differences between Igfbp5-overexpressing and Igf-null or other Igfbpoverexpressing mice. We therefore reveal a dual function for IGFBP-5, as a modulator of IGF activity and, significantly, as an IGF-independent bioactive peptide.
